Novartis to Buy Tourmaline Bio in $1.4B Acquisition Deal
Novartis has confirmed it will acquire Tourmaline Bio in a deal valued at $1.4 billion. The agreement highlights Novartis’s ambition to expand its oncology pipeline and deepen its commitment to data-driven medicine.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →